Get the Stockscreener App
0.00
0.00%
0.00
Vitro Biopharma, Inc. stock is traded at $0.00, with a volume of 0.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. Their goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.
See More
Previous Close:
$0.00
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
$1.65M
Net Income/Loss:
$-5.91M
P/E Ratio:
0.00
EPS:
-0.1707
Net Cash Flow:
$-3.03M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Name
Vitro Biopharma, Inc.
Sector
Industry
Phone
(720) 859-4120
Address
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vitro Biopharma, Inc. Stock (VTRO) Latest News
Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions - Nature
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout - Fierce Biotech
World In Vitro Transcription Enzyme MixesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - PR Newswire
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
VTRO (Vitro Biopharma) PB Ratio : 0.00 (As of Mar. 26, 2026) - GuruFocus
These 18 french biotech startups could shape tomorrow’s medicine - Labiotech.eu
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewswire
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
KDDF: advancing Korea’s oncology sector globally - Nature
How new approach methodologies are reshaping drug discovery - McKinsey & Company
Early bits of in vivo CAR-T human data emerge from biotech trials in China - Endpoints News
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - CRISPR Medicine News
Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment - ACCESS Newswire
Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire
The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report - Frontiers
Vitro Biopharma | CORRESP: CORRESP - Moomoo
Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Press Release Service: Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia - CRISPR Medicine News
Vitro Biopharma(VTRO) Stock Options Chain | Quotes & News - Moomoo
Top 5 In-Vitro Diagnostics [IVD] Companies - Fortune Business Insights
In Vivo CRO Market Size to Reach USD 13.74 Billion By 2033 - biospace.com
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer - BioInformant
Vitro Biopharma Company Profile & Introduction - Moomoo
EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov
Vitro Biopharma(VTRO) Stock Price Today | Quotes & News - Moomoo
Matinas BioPharma Demonstrates in vivo Biological Activity - GlobeNewswire
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Vitro Biopharma, Inc. (VTRO) Stock Live Price, Chart & News - CoinCodex
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care - Business Wire
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million. - marketscreener.com
Biotech - McKinsey & Company
Business of Biotechniques 2022 - BioTechniques
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
FinancialContentAytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells - FinancialContent
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - BioInformant
DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - BioInformant
Vitro Biopharma, Inc. Stock (VTRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Cap:
|
Volume (24h):